PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/03/2803315/0/en/PainReform-Reports-Successful-Head-to-Head-Comparison-of-PRF-110-Versus-Market-Leading-Post-Surgical-Analgesia-for-Extended-Postoperative-Pain-Relief.html

TEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) —  PainReform Ltd. (Nasdaq:PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today reported in vitro test results comparing the Company’s lead product, PRF-110, versus the industry leader, as a topical analgesia for postoperative pain relief.

Read more at globenewswire.com

Related news for (PRFX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.